Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
about
Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cellsIdentification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transportersReversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell lineThe major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myelomaNanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic indexNovel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1.Nucleotide-resolution mapping of topoisomerase-mediated and apoptotic DNA strand scissions at or near an MLL translocation hotspotDifferential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.Cell killing and DNA damage by etoposide in Chinese hamster V79 monolayers and spheroids: influence of growth kinetics, growth environment and DNA packaging.Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cellsRetention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpressionMultidrug resistance-associated antigens on drug-sensitive and -resistant human tumour cell lines.Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells.Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440)Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressorIdentification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells.Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines.Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.Genetic mechanisms of drug resistance. A review.Amonafide: a potential role in treating acute myeloid leukemia.Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosisAntineoplastic drug resistance and breast cancer.High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors.Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance.Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.Characterization of an etoposide-resistant human K562 cell line, K/eto.Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous geneReversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage.Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein.
P2860
Q24614785-DD6FA57C-A7AA-4545-BA54-CF4109A4E5E0Q24648348-FFC2C72C-6E89-43CF-903D-DB80FB3E2488Q24800442-BD043F73-B5E1-480F-80FA-0CA24F7BD29AQ28141571-29C2721F-3BCF-434A-AA44-DF7C16877D4DQ33644858-837DF96D-40B6-4EC0-9A1D-C34675BE868EQ34715623-CACE9170-AB11-4C7F-BFF6-899F941A7203Q34914312-F4ADE3C8-4D18-46CF-BEC0-876416B5C3A5Q35221459-1B651702-790A-4F03-9D49-29FC77FD04DAQ35975758-3816266B-BA00-45CE-A62B-29A8F90C21C3Q35976079-514C9166-D733-4245-8355-2D3027B4CEE0Q35978105-A5951D36-454D-486E-92DE-754E14EF96EBQ35983304-E6470582-E3E8-4DD0-87D5-4B28AA20FF1CQ35992775-0DB313A2-2FFE-48C5-9129-F39E90E9588CQ36080575-FBD214D1-5275-40EB-A7D9-1681654DB3A0Q36136120-19D214FA-B0AC-40CA-A8D1-5ED5707B33BDQ36292494-FA34AA87-45FF-4C50-8FA1-D42399585E45Q36422757-EA3270C0-205F-48B8-A24A-C0BA3BA1C589Q36431160-55CA8413-9F96-4C97-81DF-0B62910B55BCQ36564894-AF6F406D-D105-4B08-B41C-7C010467B474Q36615227-6AD8694C-B839-4DE0-AA83-637E9CA6C7C3Q36913097-75BBE326-DA8A-4EA0-AB23-7288AB7F81FCQ37168584-1DEB2E23-1361-4F98-BBB2-9ADAB4655D2AQ37585969-92C41B0B-849C-4EF3-BF23-F7F05BDFF351Q37679117-69FE4D0C-B990-4CCF-A91C-B34E40B3D10BQ37876908-A7599191-C743-4157-A405-11FBF449997DQ39707262-4FB1E492-145E-4ED2-B6C6-1E90EF5B8FBDQ40022761-62B60A5D-967C-4E84-9052-38B5C6E36F52Q40619705-CB80B2EB-19FF-4ED6-928C-3CE16D29F0DAQ40782940-A14C786B-6A68-4896-BA6B-E3C0596776B4Q41109056-87BBEC90-5517-49E3-91CC-5E3CA644E334Q41120819-B62217B7-D98D-4C5E-9AAE-136770FB62A2Q41202524-13474FAE-6055-4491-B334-13090A0480B6Q41571202-1CD9EF06-0000-4441-A432-14F2115F7125Q41632996-59C7B51B-0A77-4E86-9709-4697421F3A14Q41668193-596F9178-110E-43BF-96FD-D1872E693AC6Q41899243-DF6812BE-376F-4823-985D-A6172DB7E2FEQ42163923-FA60E74B-8FD1-4558-BD6E-1F7ADC7FB049Q42279792-7FD7BD90-47DB-44F0-9162-F76E31EF9EA3Q43608431-7D0D8409-6E2A-485B-A2B5-391A3F6DAE7DQ43800117-E95937D6-536B-4C5F-AA2B-C83A38F6D9F5
P2860
Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Altered catalytic activity of ...... ected for resistance to VM-26.
@en
type
label
Altered catalytic activity of ...... ected for resistance to VM-26.
@en
prefLabel
Altered catalytic activity of ...... ected for resistance to VM-26.
@en
P2093
P356
P1433
P1476
Altered catalytic activity of ...... ected for resistance to VM-26.
@en
P2093
P304
P356
10.1021/BI00424A026
P407
P577
1988-11-01T00:00:00Z